Advances in monitoring and toxicity assessment of brevetoxins in molluscan shellfish.
Herein, we describe advancements in monitoring of brevetoxins in molluscan shellfish, with respect to exposure management and control of neurotoxic shellfish poisoning (NSP). Current knowledge of the fate of brevetoxins in molluscan shellfish, and the toxic potency of brevetoxin metabolites, is presented. We review rapid assays for measuring composite brevetoxins, and methodology for measuring constituent brevetoxins, in contaminated shellfish. The applicability of in vitro methods for estimating brevetoxin burden and composite toxicity in shellfish is assessed. Specific and measurable biomarkers of brevetoxin exposure and toxicity in shellfish, and of human intoxication, are described. Their utility in regulatory monitoring of toxic shellfish and in clinical diagnosis of NSP is evaluated.
Plakas
Steven M
SM
Gulf Coast Seafood Laboratory, U.S. Food and Drug Administration, 1 Iberville Drive, Dauphin Island, AL 36528, USA. Steven.Plakas@fda.hhs.gov
Dickey
Robert W
RW
D000818:Animals; D015415:Biomarkers / Q000032:analysis; D049872:Bivalvia / Q000737:chemistry*; D004141:Dinoflagellida / Q000737:chemistry*; D004784:Environmental Monitoring / Q000379:methods*; D006801:Humans; D008387:Marine Toxins / Q000032:analysis / Q000633:toxicity; D009498:Neurotoxins / Q000032:analysis / Q000633:toxicity; D035964:Oxocins / Q000032:analysis / Q000633:toxicity; D012758:Shellfish / Q000032:analysis; D057096:Shellfish Poisoning; D018675:Toxicity Tests; D000095702:Polyether Toxins
D015415:Biomarkers; D008387:Marine Toxins; D009498:Neurotoxins; D035964:Oxocins; C053342:brevetoxin; D000095702:Polyether Toxins